| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.59B | 18.44B | 14.91B | 10.04B | 9.65B | 11.08B |
| Gross Profit | 9.66B | 8.98B | 7.05B | 4.61B | 4.36B | 5.17B |
| EBITDA | 7.01B | 6.34B | 4.91B | 3.02B | 2.87B | 3.54B |
| Net Income | 5.81B | 5.36B | 3.83B | 2.25B | 2.19B | 2.38B |
Balance Sheet | ||||||
| Total Assets | 21.90B | 21.35B | 18.74B | 14.56B | 12.00B | 12.48B |
| Cash, Cash Equivalents and Short-Term Investments | 6.69B | 6.39B | 5.85B | 6.71B | 5.43B | 4.95B |
| Total Debt | 4.48B | 4.76B | 4.98B | 5.81B | 4.49B | 2.42B |
| Total Liabilities | 11.71B | 11.48B | 10.21B | 9.38B | 7.28B | 5.90B |
| Stockholders Equity | 10.19B | 9.86B | 8.54B | 5.18B | 4.72B | 6.58B |
Cash Flow | ||||||
| Free Cash Flow | 5.85B | 5.41B | 4.26B | 1.92B | 2.87B | 2.38B |
| Operating Cash Flow | 6.38B | 6.17B | 4.65B | 2.13B | 3.18B | 2.66B |
| Investing Cash Flow | -783.59M | -708.09M | -370.61M | -244.08M | -1.64B | 2.75B |
| Financing Cash Flow | -4.96B | -4.94B | -4.00B | -623.93M | -2.39B | -3.27B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $414.17B | 40.07 | 51.72% | 0.63% | 24.91% | 39.95% | |
| ― | $159.92B | 38.78 | 99.17% | 0.59% | 22.27% | 45.32% | |
| ― | $201.81B | 34.29 | 62.26% | 0.59% | 25.66% | 46.68% | |
| ― | $413.57B | 146.69 | 4.70% | ― | 27.17% | 108.67% | |
| ― | $185.26B | 28.11 | 35.64% | 0.74% | 6.70% | -5.95% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ― | $187.56B | 2,889.21 | 0.19% | ― | -1.49% | ― |
Lam Research Corp’s recent earnings call painted a picture of robust financial performance and strategic positioning, despite facing some regulatory headwinds. The company reported record revenues and strong demand driven by AI and advanced packaging, which are bolstered by significant investments in NAND and DRAM. While challenges such as regulatory impacts in China and tariff pressures exist, the overall sentiment remained positive, emphasizing market leadership and demand growth.
Lam Research Corp faces significant risks from epidemics, pandemics, or disease outbreaks, which can severely impact its business operations and financial performance. Governmental measures to control disease spread, such as quarantines and travel bans, can restrict business activities, leading to facility closures, production delays, and supply chain disruptions. These challenges may result in increased costs, reduced revenues, and decreased profitability, potentially causing material adverse effects on the company’s financial results. Additionally, global health crises can disrupt financial markets and economic stability, affecting customer demand and the company’s access to financing.
Lam Research Corp’s recent earnings call reflected a positive sentiment overall, driven by strong financial performance and technological advancements. The company reported significant growth in the China market and positive trends in advanced packaging and high-bandwidth memory (HBM). However, challenges such as a decline in DRAM revenue, potential tariff headwinds, and uncertainty in long-term wafer fabrication equipment (WFE) spending were also highlighted.
Lam Research Corporation is a global leader in the semiconductor industry, providing innovative wafer fabrication equipment and services that enable the production of advanced chips. The company is headquartered in Fremont, California, and is recognized for its superior systems engineering and technology leadership.